Letters to the Editor
13.
14.
15.
16. Chahinian AP GD, Fuster V. Tumors of the Heart and Great Vessels. In: Holland-Frei Cancer Medicine 5th ed.; 2000. 17. Butterworth JS, Poindexter CA. Papilloma of cusp of the aortic valve. Report of a patient with sudden death. Circulation 1973; 48: 213-215. 18. Zurru MC, Romano M, Patrucco L, et al. Embolic stroke secondary to cardiac papillary fibroelastoma. Neurologist 2008; 14: 128-130. 19. Mutlu H, Demir IE, Leppo J, et al. Nonsurgical management of a left ventricular pedunculated papillary fibroelastoma: a case report. J Am Soc Echocardiogr 2008; 21: 877 e4-7. 20. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009; 374: 534-542.
Anti-oxidised-phospholipid antibodies do not correlate with specific anti-phospholipid syndrome classes, but with disease duration Claudio Musetti1; Marco Quaglia1; Tiziana Cena2; Antonietta Rizzo1; Piero Stratta1; Emanuele Albano3 1Department
of Translational Medicine, University “Amedeo Avogadro“ of East Piedmont, Novara, Italy; 2Epidemiology, University “Amedeo Avogadro“ of East Piedmont, Novara, Italy; 3Department of Health Sciences, University “Amedeo Avogadro“ of East Piedmont, Novara, Italy
Dear Sirs, Much effort has been devoted to the study of oxidation-dependent antibodies targeting oxidised phospholipid (OxPL) in the past decades (1), focusing on their putative pathogenetic and clinical role in different settings (2), including the development and progression of auto-immune diseases (3–6).
Correspondence to: Claudio Musetti, MD Department of Translational Medicine University “Avogadro”, Novara, Italy Via Solaroli 17, 28100, Novara, Italy Tel.: +39 0321 3733798, Fax: +39 0321 3733916 E-mail: [email protected] Received: June 30, 2013 Accepted after major revision: September 23, 2013 Prepublished online: October 24, 2013 doi:10.1160/TH13-06-0525 Thromb Haemost 2014; 111: 378–380
© Schattauer 2014
Since oxidised cardiolipin (OxCL) and oxidised phosphatidylserin (OxPS) might be the result of an increased endothelial damage during anti-phospholipid syndrome (APS) and systemic lupus erythematosous (SLE) (7), the prevalence of antibodies targeting OxCL (aOxCL) or OxPS (aOxPS) may be high in these patients and may relate to the degree of endothelial damage. Therefore aOxPL may be just a marker of endothelial damage or may trigger a vicious circle leading eventually to a more aggressive disease. In this pilot study we investigated whether patients with APS and/or SLE had aOxPL and if they were associated with APS classes or clinical events. We enrolled from Nephrology, Hematology and Immunology/Reumatology Units of seven hospitals 31 patients with APS: 18 primary APS (PAPS; 4 men, 14 women; mean age 52.5 ± 16.0 years), 13 pa-
21. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123: 131-136. 22. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026. 23. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Int Med 2004; 141: 745-752. 24. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008; 100: 453-461.
tients with APS associated with SLE (2 men, 11 women; mean age 43.3 ± 9.9 years); 80 patients with only SLE (14 men, 66 women; mean age 42.7 ± 14.9 years) and 40 patients with a primary GN, as controls (27 men, 13 women; mean age 56.8 ± 15.7 years). Moreover 14/80 (17.5%) of SLE patients had an aPL. Diagnosis and classification was made following the Sydney criteria for APS –including IgG and/or IgM aPL- (8) and the American College of Rheumatology criteria for SLE. The most common class of APS was class I (17/31=54.8%), followed by class IIa (5/31=16.1%) and IIb (5/31=16.1%), without any difference between PAPS and SLEassociated APS. APS patients (PAPS or SLE-associated) had suffered more thrombotic events (31/31=100%) than patients with SLE alone (5/80=6.3%) and GN controls (1/40=2.5%; p
13.
14.
15.
16. Chahinian AP GD, Fuster V. Tumors of the Heart and Great Vessels. In: Holland-Frei Cancer Medicine 5th ed.; 2000. 17. Butterworth JS, Poindexter CA. Papilloma of cusp of the aortic valve. Report of a patient with sudden death. Circulation 1973; 48: 213-215. 18. Zurru MC, Romano M, Patrucco L, et al. Embolic stroke secondary to cardiac papillary fibroelastoma. Neurologist 2008; 14: 128-130. 19. Mutlu H, Demir IE, Leppo J, et al. Nonsurgical management of a left ventricular pedunculated papillary fibroelastoma: a case report. J Am Soc Echocardiogr 2008; 21: 877 e4-7. 20. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009; 374: 534-542.
Anti-oxidised-phospholipid antibodies do not correlate with specific anti-phospholipid syndrome classes, but with disease duration Claudio Musetti1; Marco Quaglia1; Tiziana Cena2; Antonietta Rizzo1; Piero Stratta1; Emanuele Albano3 1Department
of Translational Medicine, University “Amedeo Avogadro“ of East Piedmont, Novara, Italy; 2Epidemiology, University “Amedeo Avogadro“ of East Piedmont, Novara, Italy; 3Department of Health Sciences, University “Amedeo Avogadro“ of East Piedmont, Novara, Italy
Dear Sirs, Much effort has been devoted to the study of oxidation-dependent antibodies targeting oxidised phospholipid (OxPL) in the past decades (1), focusing on their putative pathogenetic and clinical role in different settings (2), including the development and progression of auto-immune diseases (3–6).
Correspondence to: Claudio Musetti, MD Department of Translational Medicine University “Avogadro”, Novara, Italy Via Solaroli 17, 28100, Novara, Italy Tel.: +39 0321 3733798, Fax: +39 0321 3733916 E-mail: [email protected] Received: June 30, 2013 Accepted after major revision: September 23, 2013 Prepublished online: October 24, 2013 doi:10.1160/TH13-06-0525 Thromb Haemost 2014; 111: 378–380
© Schattauer 2014
Since oxidised cardiolipin (OxCL) and oxidised phosphatidylserin (OxPS) might be the result of an increased endothelial damage during anti-phospholipid syndrome (APS) and systemic lupus erythematosous (SLE) (7), the prevalence of antibodies targeting OxCL (aOxCL) or OxPS (aOxPS) may be high in these patients and may relate to the degree of endothelial damage. Therefore aOxPL may be just a marker of endothelial damage or may trigger a vicious circle leading eventually to a more aggressive disease. In this pilot study we investigated whether patients with APS and/or SLE had aOxPL and if they were associated with APS classes or clinical events. We enrolled from Nephrology, Hematology and Immunology/Reumatology Units of seven hospitals 31 patients with APS: 18 primary APS (PAPS; 4 men, 14 women; mean age 52.5 ± 16.0 years), 13 pa-
21. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123: 131-136. 22. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026. 23. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Int Med 2004; 141: 745-752. 24. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008; 100: 453-461.
tients with APS associated with SLE (2 men, 11 women; mean age 43.3 ± 9.9 years); 80 patients with only SLE (14 men, 66 women; mean age 42.7 ± 14.9 years) and 40 patients with a primary GN, as controls (27 men, 13 women; mean age 56.8 ± 15.7 years). Moreover 14/80 (17.5%) of SLE patients had an aPL. Diagnosis and classification was made following the Sydney criteria for APS –including IgG and/or IgM aPL- (8) and the American College of Rheumatology criteria for SLE. The most common class of APS was class I (17/31=54.8%), followed by class IIa (5/31=16.1%) and IIb (5/31=16.1%), without any difference between PAPS and SLEassociated APS. APS patients (PAPS or SLE-associated) had suffered more thrombotic events (31/31=100%) than patients with SLE alone (5/80=6.3%) and GN controls (1/40=2.5%; p
